Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioNTech SE (BNTX) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and annual reports on Form 20-F. As a foreign private issuer listed on Nasdaq, BioNTech uses these filings to report financial results, material agreements, strategic transactions and key corporate presentations.
Through its 6-K filings, BioNTech has furnished quarterly financial statements and operating reviews, detailing revenues from its COVID-19 vaccine franchise, collaboration income and research and development spending related to its oncology and mRNA programs. Other 6-Ks incorporate press releases and presentations covering topics such as third quarter results, R&D and AI-focused events, and strategic business updates presented at investor conferences.
Regulatory filings also document major corporate transactions and collaborations. For example, BioNTech has filed 6-Ks that attach press releases on its public exchange offer for all outstanding shares of CureVac N.V. and the subsequent completion of that acquisition, as well as a detailed description of the amended and restated global co-development and co-commercialization agreement with Bristol Myers Squibb for the bispecific antibody pumitamig (BNT327/BMS986545). These documents outline development responsibilities, cost-sharing, profit and loss sharing and intellectual property licensing arrangements.
Investors can use this page to review filings related to clinical and strategic milestones, including R&D day presentations, AI strategy updates and oncology pipeline overviews that are furnished as exhibits to Form 6-K. Stock Titan enhances access to these materials by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy documents such as financial reports, collaboration agreements and transaction-related disclosures.
For those researching BNTX stock, the filings page is a resource for understanding how BioNTech describes its business, reports its financial performance, and records significant agreements and acquisitions in the official SEC record.
BioNTech SE filed a Form 144 notifying of a proposed sale of 150,000 American Depositary Shares on 03/11/2026 for an aggregate offering price of $12,583,500.00 on the Nasdaq Global Select market. The filing lists underlying sources including 95,000 shares from a stock option exercise and 55,000 shares from a private transaction.
BioNTech files its 2025 Form 20-F annual report, describing its mRNA-focused business, COVID-19 vaccine franchise and expanding oncology and antibody-drug conjugate pipelines. The company highlights extensive regulatory, clinical, manufacturing, competitive and intellectual property risks around developing and commercializing its product candidates.
Revenue is noted as heavily dependent on its COVID-19 vaccine, with demand expected to decrease, while future growth is tied to new oncology assets such as BNT327 and ADCs. BioNTech also discloses operational and geopolitical risks from global trials and supply chains, ESG and human-rights compliance obligations, and AI-related legal and reputational uncertainties. Ordinary shares outstanding were 239,970,804 as of March 3, 2025.
BioNTech reported fourth quarter and full year 2025 results, updated 2026 guidance and outlined a major oncology-focused strategy shift. 2025 revenues were €2.9 billion while the company recorded a net loss of €1.1 billion and adjusted net loss of €0.1 billion. Cash, cash equivalents and security investments totaled €17.2 billion, providing substantial funding for its expanding cancer pipeline.
For 2026, BioNTech expects total revenues of €2.0–2.3 billion, adjusted R&D expenses of €2.2–2.5 billion and adjusted SG&A expenses of €700–800 million as it prioritizes late‑stage oncology development. Management highlighted multiple 2026 data readouts across immunomodulators, antibody‑drug conjugates and mRNA cancer immunotherapies.
The company plans an independent next‑generation mRNA venture to be led by co‑founders Ugur Sahin and Özlem Türeci, who are expected to transition by the end of 2026. BioNTech aims to become a multi‑product oncology company by 2030 with numerous planned late‑stage and potentially registrational trials.
BioNTech SE plans to support the creation of an independent biotechnology company led by co-founders Prof. Ugur Sahin and Prof. Özlem Türeci that will focus on next-generation mRNA innovations. BioNTech intends to contribute related rights and mRNA technologies in return for a minority stake, milestones and royalties.
BioNTech says its current clinical pipeline, including its COVID‑19 vaccine franchise, remains unaffected and expects to have 15 ongoing Phase 3 oncology trials by year end, with multiple late-stage data readouts in 2026. Sahin and Türeci are expected to transition to the new company’s management by the end of 2026, while BioNTech’s Supervisory Board has started searching for their successors.
BioNTech SE insider Ugur Sahin has filed a Form 144 indicating an intent to sell 858,209 American Depositary Shares (ADS), representing ordinary shares with no par value. The planned sale through Berenberg Capital Markets LLC on the Nasdaq Global Select Market has an aggregate market value of $93,870,900.42, while 240,455,450 ADS were outstanding.
The securities to be sold were acquired via stock option exercises on 11/21/2022 (856,186 ordinary shares) and 08/09/2024 (2,023 ordinary shares). Over the past three months, Sahin has already sold multiple ADS blocks, including 72,970 ADS for $7,901,797.25 on 01/14/2026 and 62,000 ADS for $7,451,792.40 on 01/22/2026.
BioNTech SE announced that its Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer, effective March 1, 2026. This is a newly created role focused on leading the company’s global people strategy.
The appointment supports BioNTech’s strategy to evolve into a multi-product oncology company by 2030, emphasizing the importance of its global, highly skilled workforce. Jimenez brings more than 20 years of international HR experience from Georg Fischer, Toyota, Johnson & Johnson, and General Mills, and will be based at BioNTech’s headquarters in Mainz, Germany.
BioNTech SE submitted a report describing a strategic business update delivered at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. On January 13, 2026, the company outlined its focus areas for 2026 and provided an overview of expected near- to longer-term milestones. The related presentation is made available as Exhibit 99.1 to this report.
BioNTech SE is using a 2026 strategic update to highlight its shift toward becoming a multi-product oncology company while relying on its COVID-19 franchise and strong balance sheet. The company expects seven late-stage oncology data readouts in 2026 and plans to have 15 Phase 3 clinical trials ongoing by year-end, across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies. By 2030+, BioNTech anticipates at least 17 late-stage or pivotal data readouts that could support multiple product launches in major tumors such as lung, breast, gynecologic and head and neck cancers.
Financially, BioNTech reported approximately €17.2 billion in cash, cash equivalents and security investments as of December 31, 2025 and in November 2025 raised its 2025 revenue guidance to €2.6–2.8 billion while lowering expense guidance ranges. For 2026, it anticipates a modest decline in Comirnaty revenues and does not expect to recognize revenues from oncology product sales, while revenues from its Bristol Myers Squibb collaboration are expected to be broadly in line with 2025.
BioNTech SE has effectively completed its exchange offer for CureVac N.V. shares. As of the expiration of the subsequent offering period at 12:01 a.m. New York City time on December 18, 2025, a total of 195,341,219 CureVac shares, representing approximately 86.75% of CureVac’s issued and outstanding capital, were validly tendered.
BioNTech expects to promptly pay for all CureVac shares tendered in the offer and then carry out a post-offer reorganization. After this reorganization, CureVac will no longer be publicly traded, its shares will be delisted from Nasdaq, and the shares will be deregistered under the Exchange Act, ending CureVac’s ongoing SEC reporting obligations.
BioNTech SE reports that it has completed its exchange offer for all outstanding shares of CureVac N.V., following the expiration of the subsequent offering period. This means CureVac is now being acquired by BioNTech through a share-exchange structure rather than a cash-only deal. The company states that this step closes the acquisition process and is intended to strengthen BioNTech’s position in the mRNA field. The press release describing the transaction is included as an exhibit and this report is incorporated by reference into BioNTech’s existing Form F-4 registration statement.